Infectious Disease Advisor: Single-tablet BIC/LEN noninferior to BIC/FTC/TAF in suppressed HIV
A phase 3 clinical trial, ARTISTRY-2, has demonstrated that a single-tablet regimen of bictegravir and lenacapavir is noninferior to standard treatments for HIV-1. The findings suggest a simplified treatment option for patients who are already virologically suppressed.
Why it matters
Simplifying antiretroviral therapy can significantly improve patient adherence and quality of life for those living with HIV.
Results of a phase 3, noninferiority trial support bictegravir plus lenacapavir (BIC/LEN) as an effective single-tablet antiretroviral therapy (ART) for virologically suppressed patients with HIV-1 infection. These study findings were published in The Lancet HIV .
The report summarizes medical research findings objectively.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in